STEPHEN CASO: Open Payments
NPI 1083916985 · TEMECULA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,365 in 85 payments from 28 companies in 2025. Trend: 2023 $2,270 · 2024 $2,939 · 2025 $2,365
Food & beverage: $2,365
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 14 | $323 |
| Gilead Sciences, Inc. | 6 | $265 |
| GlaxoSmithKline, LLC. | 8 | $218 |
| Lilly USA, LLC | 7 | $205 |
| Amgen Inc. | 5 | $202 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $136 |
| Novo Nordisk Inc | 6 | $127 |
| Inspire Medical Systems, Inc. | 2 | $114 |
| Phadia US Inc. | 2 | $112 |
| ABBVIE INC. | 4 | $67 |
Products named: TRELEGY ELLIPTA, MOUNJARO, XIFAXAN, BREZTRI, AIRSUPRA, INSPIRE, ImmunoCAP, FARXIGA.
Industry payments across CA — which companies pay providers there.
